Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
暂无分享,去创建一个
P. Fenaux | M. Fontenay | Sophie Park | U. Platzbecker | V. Santini | O. Kosmider | O. Beyne-Rauzy | F. Dreyfus | G. Zini | V. Andrieu | E. Balleari | A. Guerci | M. Passet | E. Masala | E. Bulycheva
[1] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[3] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[4] A. Stamatoullas,et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? , 2013, Blood.
[5] D. Neuberg,et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Bosi,et al. Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients , 2012, Clinical Cancer Research.
[7] B. Quesnel,et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.
[8] V. Viallon,et al. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes , 2010, Haematologica.
[9] G. Ossenkoppele,et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. , 2010, Blood.
[10] D. Cella,et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). , 2009, Blood.
[11] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[12] M. Cazzola,et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[14] I. Dybedal,et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.